The Food and Drug Administration approved bimekizumab-bkzx, sold as Bimzelx, for adults with moderate-to-severe plaque psoriasis this week, introducing the first U.S.-approved psoriasis therapy designed to selectively inhibit both interleukin-17A and interleukin-17F. The approval gives dermatologists another biologic option for patients who are candidates for systemic therapy or phototherapy and follows a phase 3 program in which large majorities of treated patients achieved near-complete or complete skin clearance.

FDA’s Drug Trials Snapshot says the agency approved Bimzelx on October 17 based primarily on two placebo-controlled trials involving 839 adults, with supportive safety data from two additional active-controlled trials involving 1,169 patients. The recommended psoriasis regimen is 320 milligrams by subcutaneous injection at weeks 0, 4, 8, 12 and 16, followed by dosing every eight weeks for most patients.

Dual IL-17 blockade distinguishes the drug

Psoriasis is driven by immune signaling that accelerates skin-cell turnover and sustains inflammation. Several existing biologics target the IL-17 pathway, but bimekizumab is designed to neutralize both IL-17A and IL-17F. UCB, the drug’s manufacturer, said in its approval announcement that Bimzelx is the first approved U.S. psoriasis treatment built around selective inhibition of both cytokines.

The mechanistic distinction matters because IL-17A and IL-17F are related inflammatory mediators that can be elevated in psoriatic lesions. Blocking both may suppress a wider portion of the inflammatory signal than inhibiting IL-17A alone, although the clinical value of that broader blockade must be weighed against adverse effects and individual patient characteristics.

Phase 3 trials showed rapid and deep skin clearance

The approval rests on a group of randomized studies that repeatedly found high response rates. In the placebo-controlled BE READY trial, published in The Lancet, adults with moderate-to-severe plaque psoriasis received bimekizumab or placebo through week 16 before responders entered randomized maintenance dosing. The study found high rates of PASI 90 response—meaning at least a 90% improvement in the Psoriasis Area and Severity Index—and showed that responses could be maintained with dosing every four or eight weeks.

The companion BE VIVID trial compared bimekizumab with both placebo and ustekinumab over 52 weeks. At week 16, bimekizumab produced markedly higher PASI 90 and Investigator’s Global Assessment responses than placebo, while also outperforming the active comparator on key skin-clearance measures.

FDA’s own trial summary reports that in the two pivotal placebo-controlled studies, 77% and 76% of patients receiving Bimzelx had already reached PASI 75 by week four, compared with 2% and 1% of placebo recipients. That early separation supports UCB’s description of the drug as producing a rapid response rather than only a high final clearance rate.

Head-to-head trials tested the new drug against established biologics

The clinical program also included direct comparisons with commonly used therapies. In the BE SURE trial, published in the New England Journal of Medicine, 86.2% of bimekizumab-treated patients achieved PASI 90 at week 16 compared with 47.2% of patients receiving adalimumab. The trial found bimekizumab statistically superior on that endpoint and on the proportion of patients rated clear or almost clear.

A separate New England Journal trial, BE RADIANT, compared bimekizumab with secukinumab, an established IL-17A inhibitor. Bimekizumab produced higher rates of complete skin clearance through the trial’s main comparison periods, supporting the hypothesis that dual IL-17A and IL-17F inhibition can yield deeper responses than IL-17A inhibition alone in some patients.

Across BE READY, BE VIVID and BE SURE, UCB said 85% to 91% of bimekizumab-treated patients were clear or almost clear at week 16, and 59% to 68% achieved complete clearance. Those percentages come from different trials with different comparators, so they should not be treated as a single pooled estimate, but they describe a consistently high level of response across the phase 3 program.

Safety will shape how the drug is used

Greater pathway suppression also brings tradeoffs. Oral candidiasis occurred more frequently with bimekizumab than with some active comparators, a finding seen repeatedly in the clinical program. The BE SURE study reported upper respiratory infections, oral candidiasis, hypertension and diarrhea among common adverse events, while BE RADIANT found substantially more oral candidiasis with bimekizumab than with secukinumab.

The prescribing information also requires clinicians to consider infection risk and other safety issues before starting therapy. Patients should be evaluated for tuberculosis, kept current on age-appropriate immunizations and monitored for infections during treatment. The practical decision is therefore not simply whether Bimzelx can clear psoriasis effectively, but whether its benefit-risk profile fits a particular patient’s disease severity, treatment history and medical conditions.

The new approval expands an already crowded biologic market in psoriasis, where highly effective drugs now target TNF, IL-12/23, IL-23 and IL-17 pathways. Competition increasingly centers not on whether a drug improves plaques at all, but on how quickly and how completely it clears skin, how durable that response is, how often injections are required and what safety liabilities accompany the mechanism.

As of Saturday, Bimzelx adds a new mechanism to that competition. Its U.S. approval validates dual IL-17A/IL-17F inhibition after years of comparative trials and gives patients another route toward the increasingly realistic treatment goal of nearly or completely clear skin.